NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT06120972 2025-02-12
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
University of Pittsburgh
Phase 2 Withdrawn
NCT05967286 2024-03-20
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05209529 2024-02-23
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05411679 2023-06-12
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Ellipses Pharma
Phase 2 Withdrawn
NCT04239014 2021-03-10
DUETTE
AstraZeneca
Phase 2 Withdrawn
NCT01661868 2012-08-21
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Withdrawn